Xiaoling Weng

1.9k citations
31 papers · 696 indexed · h-index 16
Topics
Epigenetics and DNA Methylation (8 papers)Cancer-related molecular mechanisms research (6 papers)Cancer-related gene regulation (5 papers)

In The Last Decade

Xiaoling Weng

31 papers receiving 690 citations

Peers

Xiaoling Weng
Comparison fields: 5 of 91
  • Molecular Biology 382
  • Cancer Research 187
  • Oncology 160
  • Pulmonary and Respiratory Medicine 91
  • Surgery 83
Replace Rachel A. Egler with:
Rachel A. Egler United States
Petra Kleiblová Czechia
Saioa Goñi Spain
Alexander M. Tseng United States
Hongping Yu China
Noriyuki Yatabe Japan
Mei-Hsuan Wu Taiwan
Hirokazu Usui Japan
Jiasen Xu China
Akiko Fujimura Japan
Xiaoling Weng relative to Rachel A. Egler United States Rachel A. Egler's profile →
Citations per field
00.5×1.5×1.9×
Rachel A. Egler · 1×
Citations per year

Countries citing papers authored by Xiaoling Weng

Since Specialization
Citations

This map shows the geographic impact of Xiaoling Weng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoling Weng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoling Weng more than expected).

Fields of papers citing papers by Xiaoling Weng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoling Weng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoling Weng. The network helps show where Xiaoling Weng may publish in the future.

Co-authorship network of co-authors of Xiaoling Weng

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoling Weng. A scholar is included among the top collaborators of Xiaoling Weng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoling Weng. Xiaoling Weng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 6
2 3
3 3
4 5
5 15
6 52
7 5
8 12
9 50
10 86
11 8
12 16
13 19
14 17
15 20
16 30
17 7
18 35
19 18
20 37

About Xiaoling Weng

Xiaoling Weng is a scholar working on Cancer Research, Obstetrics and Gynecology and Oncology, having authored 31 papers that have together received 696 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (8 papers), Cancer-related molecular mechanisms research (6 papers) and Cancer-related gene regulation (5 papers). The work is most often cited by research in Cancer Research (187 citations), Obstetrics and Gynecology (62 citations) and Aging (12 citations). Xiaoling Weng has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Fatao Liu, Junyi Ye, Daizhan Zhou, Yun Liu, Lin He, Hong Zhang, Mengyuan Kan, Lidan Hou, Xiangjun Meng and Zhaoyuan Hou. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026